Document is current
Any future updates will be listed below
-
Authors
Naro, Chiara
Antonioni, Ambra
Medici, Vanessa
Caggiano, Cinzia
Jolly, Ariane
de la Grange, Pierre
Bielli, Pamela
Paronetto, Maria Paola
Sette, Claudio https://orcid.org/0000-0003-2864-8266
-
Funding
Funding for this research was provided by:
Fondazione AIRC per la ricerca sul cancro ETS (IG23416)
Fondazione AIRC per la ricerca sul cancro ETS (MFAG21899)
Fondazione AIRC per la ricerca sul cancro ETS (IG27896)
Ministero della Salute (Ricerca Corrente 2022)
Ministero della Salute (RF-2016-02363460)
- License Information
-
More Information
Article History
Received: 1 December 2023
Accepted: 15 February 2024
First Online: 27 February 2024
Declarations
:
: Our study highlights the cis-acting regulatory features underlying susceptibility to transcriptional and post-transcriptional variations induced by splicing-targeting drugs; it reveals IR as the prominent pattern induced by both direct (Ind/PlaB) and indirect (THZ531) inhibition of splicing and uncovers the 3’-end mRNA processing as a druggable vulnerability for advanced PC.
